M
Mark DeMario
Publications - 1
Citations - 289
Mark DeMario is an academic researcher. The author has contributed to research in topics: Cytotoxic T cell & Lung cancer. The author has an hindex of 1, co-authored 1 publications receiving 73 citations.
Papers
More filters
Journal ArticleDOI
A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer.
Patrick A. Ott,Siwen Hu-Lieskovan,Bartosz Chmielowski,Ramaswamy Govindan,Aung Naing,Nina Bhardwaj,Kim Margolin,Mark M. Awad,Matthew D. Hellmann,Jessica J. Lin,Terence W. Friedlander,Meghan E. Bushway,Kristen N. Balogh,Tracey E. Sciuto,Victoria Kohler,Samantha J. Turnbull,Rana H. Besada,Riley R. Curran,Benjamin Trapp,Julian Scherer,Asaf Poran,Dewi Harjanto,Dominik Barthelme,Ying S. Ting,Jesse Z. Dong,Yvonne Ware,Yuting Huang,Zhengping Huang,Amy Wanamaker,Lisa D. Cleary,Melissa A. Moles,Kelledy Manson,Joel Greshock,Zakaria S. Khondker,Ed Fritsch,Michael S. Rooney,Mark DeMario,Richard B. Gaynor,Lakshmi Srinivasan +38 more
TL;DR: The first open-label, phase Ib clinical trial of a personalized neoantigen-based vaccine, NEO-PV-01, in combination with PD-1 blockade in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer demonstrated that the regimen was safe, with no treatment-related serious adverse events observed.